TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01732926
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg tablet administered orally twice daily
Study: NCT01732926
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
Study: NCT01732926
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
Study: NCT03348969
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant Mitomycin C
Study: NCT02490878
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT02544113
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with thymoglobulin and delayed CNI post OLT
Study: NCT00487422
Drug: prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 mg o.d.
Study: NCT00487422
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg o.d.
Study: NCT01023308
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat was administered 3x week ( 2 weeks on 1 week off)
Study: NCT01023308
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib was administered 2 x week ( 2weeks on 1 week off)
Study: NCT01023308
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was adminstered on day of Bortezomib and the day after Bortezomib administration
Study: NCT03348826
Drug: Sodium Bicarbonate 8.4% Solution for Injection
Normalized name: Sodium Bicarbonate 8.4% Solution for injection
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mL injection into line with up to 2 injections administered
Study: NCT03348826
Drug: Alteplase Injectable Solution
Normalized name: alteplase Injection
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL injection into line with up to 2 injections administered
Study: NCT01087723
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03638635
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal injection of bupivacaine into fascial layer.
Study: NCT03638635
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abdominal injection of bupivacaine liposome into fascial layer.
Study: NCT02840175
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
Study: NCT02840175
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
Study: NCT02840175
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study: NCT02840175
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will be tapered from every 4 weeks to every 6 weeks for 24 weeks
Study: NCT00168805
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily
Study: NCT00168805
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg once daily
Study: NCT00168805
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 220 mg once daily
Study: NCT01074437
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
Study: NCT00449202
Drug: oleoyl-estrone (MP 101)
Normalized name: oleoyl tyrosine
DrugBank: Oleoyl-estrone (DB04870)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03551197
Drug: Budesonide and formoterol bid
Normalized name: formoterol and budesonide
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
Study: NCT04122560
Drug: Fluconazole 200mg tab
Normalized name: FLUCONAZOLE 200MG TAB
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO dose of 400mg
Study: NCT04122560
Drug: Fluconazole 2 MG/ML
Normalized name: fluconazole 2 MG/ML
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV dose of 400mg
Study: NCT03685032
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
Study: NCT03685032
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
Study: NCT03685032
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
Study: NCT01281553
Drug: Cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 mg/kg suspension q.i.d.for 8 weeks.
Study: NCT01475019
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 120 mg, three times daily, for six months
Study: NCT01475019
Drug: Sibutramine
Normalized name: Sibutramine
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 10 mg, once daily, for six months
Study: NCT02701582
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: if Mean arterial pressure (MAP) is \< = 65, Stroke volume variation (SVV) \< 13 and Cardiac Index is \>=2.2 Phenylephrine is administered
Study: NCT04494425
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan by intravenous infusion
Study: NCT04494425
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
Study: NCT04494425
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
Study: NCT03326050
Drug: Gemifloxacin
Normalized name: Gemifloxacin
DrugBank: Gemifloxacin (DB01155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemifloxacin 320Mg Oral Tablet once daily
Study: NCT03326050
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cipro 750 tablet twice daily
Study: NCT03326050
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 150Mg Capsule twice daily
Study: NCT01189318
Drug: Quetiapine Fumarate Extended Release
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
Study: NCT03199261
Drug: rE-4 Freeze-dried Powder
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
Study: NCT00396097
Drug: Genotropin
Normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Study: NCT00981929
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg single oral dose
Study: NCT03058237
Drug: Arbaclofen Placarbil SR
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
Study: NCT03058237
Drug: Arbaclofen Placarbil MR Prototype A
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
Study: NCT03058237
Drug: Arbaclofen Placarbil MR Prototype B
Normalized name: Arbaclofen Placarbil
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
Study: NCT03058237
Drug: Arbaclofen Placarbil IR
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
Study: NCT01647152
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00209222
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antibody
Study: NCT00209222
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00209222
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: corticosteroide
Study: NCT00209222
Drug: Cisplatinum
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00209222
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00209222
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: corticosteroide
Study: NCT00209222
Drug: BCNU
Normalized name: BCNU
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00209222
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00209222
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00209222
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: growth factor
Study: NCT03785210
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg intravenous (IV) every 4 weeks
Study: NCT03785210
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg by mouth (PO) daily
Study: NCT03785210
Drug: oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
Study: NCT04004793
Drug: Dapagliflozin 10 MG Oral Tablet
Normalized name: dapagliflozin 10 mg oral tablet
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
Study: NCT02026973
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02026973
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02026973
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00360750
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360750
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360750
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00360750
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02720198
Drug: Levomilnacipran
Normalized name: Levomilnacipran
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
Study: NCT02720198
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
Study: NCT04449549
Drug: Nilotinib and Paclitaxel
Normalized name: Nilotinib
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
Study: NCT00293332
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
Study: NCT00293332
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
Study: NCT03842696
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant
Study: NCT03842696
Drug: Tacrolimus (or cyclosporine)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
Study: NCT03334747
Drug: Coartem
Normalized name: Coartem
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control Arm
Study: NCT03842696
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.
Study: NCT04501107
Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of IMP1 during a 12-hour euglycaemic clamp.
Study: NCT04501107
Drug: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of IMP2 during a 12-hour euglycaemic clamp.
Study: NCT02642159
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
Study: NCT02642159
Drug: Statins
Normalized name: Endostatins
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins at stable dose without other LMT as clinically indicated.
Study: NCT02642159
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02642159
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02642159
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02642159
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT04448964
Drug: JNJ-70033093
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-70033093 will be administered orally as per assigned treatment sequence.
Study: NCT03829501
Drug: Alomfilimab
Normalized name: Alomfilimab
DrugBank: Alomfilimab (DB16681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human anti-ICOS monoclonal antibody
Study: NCT03829501
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An anti-PD-L1 monoclonal antibody
Study: NCT04448821
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single administration of metformin
Study: NCT04448821
Drug: Metformin + Nilotinib
Normalized name: Nilotinib
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Coadministration of metformin and nilotinib
Study: NCT01039558
Drug: ecabet sodium
Normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
Study: NCT01039558
Drug: lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
Study: NCT02324088
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02324088
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03092323
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
Study: NCT03742232
Drug: Macrogol 4000
Normalized name: Macrogol 4000
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
Study: NCT02025361
Drug: intrarectal lidocaine gel
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrarectal local anesthetic application
Study: NCT02025361
Drug: periprostatic nerve blockade
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: periprostatic local anesthetic application
Study: NCT00105521
Drug: Sarizotan
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan will be administered twice daily.